Search
for
Sort by
Research
90-120 / 1000+ results
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Janus kinase inhibitors in dermatology: A systematic review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Topical Janus kinase inhibitors: A review of applications in dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research A novel therapeutic paradigm for patients with extensive alopecia areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
research Emerging drugs for alopecia areata: JAK inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
research Reporting on Adverse Clinical Events
The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
research Building and Crossing the Translational Bridge: 2016 Alopecia Areata Research Summit Highlights
The summit aimed to speed up finding treatments for alopecia areata.
research Disorders of the Scalp and Hair
Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.
research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis
Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Prescribers alerted to potential adverse effects of finasteride and montelukast
research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.